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Abstract  
Aim: Pre-clinical evaluation of a cytotoxic copper(II) complex formulated in long circulating 
nanoliposomes for melanoma treatment.  
Materials & Methods: Liposomal nanoformulations of the copper-complex were characterized in 
terms of thermodynamic behavior (differential scanning calorimeter), pH-sensitivity 
(spectrophotometry) and antiproliferative effects against murine melanoma B16F10 cells in vitro. 
Preclinical studies were performed in a C57BL/6 syngeneic melanoma model. 
Results: Nanoformulations were thermodynamically stable, CHEMS-containing nanoliposomes were 
pH-sensitive and preserved the antiproliferative properties of the copper compound. These 
nanoformulations significantly impaired tumour progression in vivo, devoid of toxic side effects, 
compared to control mice or mice treated with the free metallodrug.  
Conclusions: Copper-complex-containing nanoliposomes demonstrate high anticancer efficacy and 
safety, constituting a step forward to the development of more effective therapeutic strategies against 
melanoma. 
 
Keywords 
Melanoma; Copper 1,10-phenanthroline complex; Nanoliposomes; pH-triggered delivery; Syngeneic 
murine model. 
  
Introduction 
Melanoma derives from the malignant transformation of melanocytes. When detected and 
treated at an early stage, most melanoma cases are curable. However, once it progresses to the 
metastatic state, treatments often fail, resulting in 80% of deaths related to skin cancers. Moreover, 
an increasing incidence, combined with the limited effectiveness of current chemotherapeutic 
approaches, pose many challenges for the successful treatment of metastatic melanoma [1]. In this 
context, to expand the current repertoire of cancer treatments and to circumvent limitations 
associated with resistances to current therapies, the identification of new drugs with high potency and 
novel mechanisms of action is of outmost importance.  
The widespread success of the Pt(II) complex cisplatin in the clinic for the treatment of various 
tumours has placed coordination chemistry of metal-based drugs in the frontline for fighting cancer 
[2]. In this field, copper-based complexes (mostly Cu2+; Figure 1) have been investigated as new 
generation metallodrugs on the assumption that endogenous metals may be less toxic for normal 
cells with respect to cancer cells [3,4]. For example, the cytotoxic dinuclear Cu2+ complex [Cu(phen)2]+ 
(phen = 1,10-phenanthroline) has been reported to bind at the minor groove of DNA and to mediate 
single-stranded breaks through oxidation of deoxyribose [5]. Recent advances have seen copper 
complexes containing a phenanthroline-type ligand and with the general formula [Cu(N^N)(O^N)]+ or 
[Cu(N^N)(O^O)]+ – from the Casiopeína class – entering clinical trials [6]. For example, the Cu2+ 
complex named Casiopeína IIgly (Cas IIgly, Figure 1) is currently under investigation as a potential 
new anticancer drug, through apoptosis via a mitochondrial pathway, originated from reactive oxygen 
species (ROS)-mediated dysfunction [7,8]. More recently, Kellett and coworkers reported the complex 
[Cu(o-phthalate)(phen)] as an intracellular ROS-active cytotoxic agent [9] and on other Cu2+ 
complexes featuring phen ligands and endowed with antiproliferative effects. The latter were able to 
catalyze intracellular superoxide (O2•−) and singlet oxygen (1O2) formation with radical species, 
mediating oxidative damage within nuclear DNA, in the form of double strand breaks, as well as in 
mitochondria, in terms of membrane depolarization [10].  
Interestingly, Cu(II) complexes have also been recently described as able to inhibit the 
aquaporins [11], membrane water and glycerol channels often abnormally expressed in tumors of 
different origins [12], suggesting an additional anticancer mechanism of action for these metallodrugs. 
Despite the numerous promising reports, the translation of metal-based compounds into 
clinical trials is frequently hampered by inherent toxic side effects [13]. Furthermore, metallodrugs are 
generally known to undergo ‘speciation’ in the biological environment, defined as the formation of 
different compound’s species from the original one upon its reaction with biomolecules, buffer 
components and the redox environment [14]. Such reactivity may lead to the de-activation of the 
pharmacologically active species and, therefore, should be limited and/or controlled. To overcome 
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these drawbacks and to increase the therapeutic benefit of metal-based compounds, new strategies 
come into play, namely the use of nanotechnological approaches for targeted delivery.  
Nano lipidic systems show great potential as carriers for antitumour drugs following adsorption 
onto their surface or incorporation within their core. These nanocarriers are able to improve the 
stability of the associated compounds [15], and the inclusion of ligands at their surface may be 
accomplished, promoting a specific targeting towards the site of action, thus minimizing toxic side 
effects and, ultimately, increasing the therapeutic effect [16]. In this regard, nanoliposomes emerge as 
invaluable tools in drug delivery, being the most extensively studied and successful lipid-based 
nanosystem. A repertoire of advantageous features includes biocompatibility, biodegradability of their 
main constituents, low toxicity, and the ability to incorporate both hydrophilic and hydrophobic 
compounds [17–19]. Furthermore, several liposomal nanoformulations for the treatment of human 
diseases are currently in clinical use, and many more in clinical trials [20]. In the case of melanoma, 
the application of putative nanotechnological therapeutic approaches has been providing encouraging 
results (reviewed in: [21,22]).  
It is well-known that nanoliposomes are able to accumulate in regions of enhanced vascular 
permeability, as those found in inflammatory [23] and tumour pathologies [17,18,22,24]. This effect 
has been described as the enhanced permeation and retention (EPR) effect [25,26]. For taking 
advantage of this effect, long blood circulation times are required, and the drug should remain 
associated within nanoliposomes [27]. Moreover, the microenvironment of solid tumours, as in the 
case of melanoma, is slightly acidic, exhibiting pH values around 6, in contrast to pH 7.4 displayed by 
healthy tissues [28,29]. Combining these two features, a pH-triggered Cuphen release from long 
circulating nanoliposomes constituted one of the goals of the present work.  
In our previous work [30], the Cu2+ complex, Cuphen [Cu(phen)Cl2] (Figure 1), was 
successfully incorporated in long circulating nanoliposomes, demonstrating antiproliferative effects 
towards different tumour cell lines and absence of in vivo toxicity after parenteral administration in 
healthy mice [30]. In the present study, we designed Cuphen long circulating nanoliposomes and 
tested their therapeutic effect in a syngeneic murine melanoma model, following an optimization of 
experimental conditions. Overall, this study provides a robust basis in the area of nanomedicine using 
metal-based compounds as an improved therapeutic strategy against melanoma.  
  
Material and methods 
Chemical products  
Cuphen and 1,10-phenantroline were purchased from Sigma and the clinical grade 5-Fluorouracil (5-
FU) was kindly supplied by Hospital de Santa Maria, Lisboa, Portugal. The pure phospholipids, 
phosphatidylcholine (PC), dimyristoyl phosphatidylcholine (DMPC), cholesteryl hemisuccinate 
(CHEMS) and distearoyl phosphatidylethanolamine covalently linked to poly(ethylene glycol) 2000 
(DSPE-PEG), used for the preparation of liposomal nanoformulations, were purchased from Avanti 
Polar Lipids (AL, USA). Cholesterol (Chol) was acquired from Sigma (Sigma-Aldrich, MO, USA). 
Deionized water (Milli-Q system; Millipore, Tokyo) was used in all experiments. Nuclepore Track-Etch 
Membranes were purchased from Whatman Ltd (NY, USA). Culture media and antibiotics were 
obtained from Invitrogen (Life Technologies Corporation, NY, USA). Reagents for cell proliferation 
assays were purchased from Promega (WI, USA). All the remaining chemicals used were of analytical 
grade.  
 
Animals 
Male C57Bl/6 mice 8–10 weeks old were purchased from Charles River (Barcelona, Spain). Animals 
were kept under standard hygiene conditions, fed commercial chow, and given acidified drinking 
water ad libitum.  
All animal experiments were conducted according to the animal welfare organ of the Faculty of 
Pharmacy, University Lisbon, approved by the competent national authority Direção-Geral de 
Alimentação e Veterinária (DGAV) and in accordance with the EU Directive (2010/63/UE) and 
Portuguese laws (DR 113/2013, 2880/2015 and 260/2016). 
 
Cell line culture conditions 
Murine melanoma B16F10 (ATCC#CRL-6475) cell line was maintained in Dulbecco’s Modified 
Eagle’s medium (DMEM) with high-glucose (4500 mg/l), supplemented with 10% fetal bovine serum 
and 100 IU/ml of penicillin and 100 μg/ml streptomycin (Invitrogen) (hereafter designated complete 
medium). Cells were kept at 37°C, under a 5% CO2 atmosphere. Maintenance of cultures was 
performed every 2-3 days, until cells reached a confluence of about 80%.  
 
Nanoliposomes preparation 
Nanoliposomes composed of the selected phospholipids were prepared by the dehydration–
rehydration method [30,31]. Long circulating nanoliposomes were produced by including DSPE-PEG. 
Chol or CHEMS were also included in the lipid compositions. For all the nanoformulations, an initial 
lipid concentration of 20 μmol/ml was used. Briefly, the selected phospholipids were dissolved in 
chloroform and the lipid solution was evaporated (Buchi R-200 rotary evaporator, Switzerland) to 
obtain a thin lipid film in a round-bottom flask. The lipid film was then dispersed with a Cuphen 
aqueous solution (750 μM), and the so-formed suspension was frozen (-70°C) and lyophilized 
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(Freeze dryer, CO, USA) overnight. The rehydration of the lyophilized powder was performed in PBS 
buffer, pH 7.4 in two steps, to enhance the Cuphen incorporation [32]. The so-formed liposomal 
suspension was then filtered, under nitrogen pressure (10–500 lb/in2), through polycarbonate 
membranes of appropriate pore size until an average vesicle size of 0.1 μm was obtained, using an 
extruder device (Lipex: Biomembranes Inc., Vancouver, Canada). The separation of non-incorporated 
Cuphen was performed by ultracentrifugation at 250,000×g, for 120 min, at 15°C in a Beckman LM-80 
ultracentrifuge (Beckman Instruments, Inc, CA, USA). Finally, the pellet was suspended in PBS 
buffer. Unloaded nanoliposomes were also prepared with the same lipid compositions.  
 
Nanoliposomes characterization 
Nanoliposomes were characterized in terms of incorporation parameters, mean size, and surface 
charge. Loading capacity was defined as the final Cuphen to lipid ratio (Cuphen/Lip)f and the 
incorporation efficiency (I.E.) in percentage was determined according to the following formula: 
I.E. (%) = ቀCuphenLip ቁfቀCuphenLip ቁi x 100 
Cuphen was quantified spectrophotometrically at 270 nm ( = 33,000 M-1 cm-1) after disruption of the 
nanoliposomes with ethanol [30]. Linearity of calibration curves was ensured from 2.5 to 25 μM (R² = 
0.9997; Slope: 0.0309 ± 0.0002; Y-intercept [x = 0]: -0.0078 ± 0.0010). Lipid content was determined 
using an enzyme-linked colorimetric method , Phospholipids Choline oxidase-Peroxidase (Spinreact, 
Spain).  
 
Differential Scanning Calorimetry (DSC) 
DSC measurements were performed in a calorimeter DSC Q200, TA Instruments, USA. Thermal 
analysis was carried out using heating and cooling rates of 3°C/minute, ranging from 15 to 40°C for 
DMPC:Chol:DSPE-PEG (F4) and DMPC:CHEMS:DSPE-PEG (F6). Thermal cycles were repeated on 
different samples to ensure constancy and reproducibility of data. The reference pan was empty. Data 
analysis was performed using TA Universal Analysis program. The transition temperature (Tc) of 
phospholipids was taken at the interception of the baseline with the tangents of the right and left side 
of the heating curve. The enthalpy of Tc was obtained from the area under the peaks and normalized 
to phospholipid content [31]. 
 
Assessment of pH-sensitive properties 
Cuphen nanoformulations, DMPC:Chol:DSPE-PEG (F4) and DMPC:CHEMS:DSPE-PEG (F6), were 
incubated in PBS buffer at three different pH values, 4.5, 6 and 7.4, for 90 min, at 37oC, under stirring. 
At the end of the incubation period, the separation of released Cuphen was performed by 
ultracentrifugation at 250,000×g, for 120 min, at 15°C in a Beckman LM-80 ultracentrifuge. 
Nanoliposomes were suspended in PBS buffer according to the initial volume, and Cuphen and 
phospholipid contents determined spectrophotometrically as described above. The stability was 
defined as the ratio in percentage between Cuphen to lipid ratio after incubation at pH 4.5, 6 or 7.4 
and the Cuphen to lipid ratio before incubation at pH 7.4, according to the following formula: 
 (CuphenLip ) f pH ሺ4.5 / 6 / 7.4ሻ(CuphenLip ) i pH 7.4 x 100 
 
Cytotoxicity evaluation 
B16F10 murine melanoma cell viability was evaluated in the absence (control) or presence of 
increasing concentrations of Cuphen, in free and liposomal forms, by the MTS assay [30].  
Cells at a concentration of 7.5 × 103 cells/ml were placed in 96-well plates (200 μl) for 24 h in culture 
conditions specified above [30]. Afterwards, complete medium was replaced, and cells treated with 
Cuphen in free or liposomal forms, at concentrations ranging from 0.2 to 12 μM, or no addition 
(control). Unloaded nanoliposomes constituted another control group, using the same lipid 
concentrations as in Cuphen nanoformulations. After 72 h, complete medium was removed and 
replaced with 100 μl of incomplete medium plus 20 μl of MTS. Absorbance was measured at 490 nm 
in a microplate reader Model 680 (Bio-Rad, CA, USA) after an incubation period of 2 h at 37oC. The 
background absorbance (incomplete medium) was subtracted from all the absorbance readings. Cell 
proliferation analysis was carried out in GraphPad Prism®5 (GraphPad Software, CA, USA). Values 
were plotted and fit to a standard inhibition log dose-response curve to generate the IC50 values. A 
total of three independent experiments, with six replicates per condition, were carried out.  
 
Tumour syngeneic mouse model  
For syngeneic tumour induction, a total of 5x105 or 1×105 B16F10 murine melanoma cells were 
suspended in PBS (100 µl) and injected subcutaneously (s.c.) in the right flank of C57Bl/6 male mice 
[33,34]. Tumours became palpable around 8 days after s.c. injection of B16F10 cells and treatment 
schedule was initiated. Mice were randomly divided in groups of five and received the formulations 
under study by intravenous (i.v.) route, three times a week, for two weeks. Negative control group 
received PBS (Control); positive control group received 5-FU at 40 mg/kg of body weight (5-FU); and 
Cuphen in the free form (Free Cuphen) or incorporated in long circulating nanoliposomes (F1, F4 and 
F6) was administered at 2.5 mg/kg body weight. Mice were monitored every day for pain or distress 
and body weight was registered two times a week. Tumour size was regularly measured using a 
digital caliper and respective volumes were calculated according to the formula: V (mm3) = (L x W2)/2, 
where L and W represent the longest and shortest axis of the tumour, respectively. Relative tumour 
volumes (RTV) were determined for each animal, as the ratio between volumes at the indicated day 
and volumes at the beginning of treatment. Three days after the final treatment, mice were 
euthanized, blood was collected, and primary tumours were excised, weighed and a portion was 
9 
 
stored at -80oC for further analysis. Spleen, liver, kidneys and lungs were excised and weighed. 
Tissue index was calculated according to the formula: 
Tissue index = √ organ weightanimal weight x 100 
 
Hepatic biochemical parameters 
Serum was isolated from the blood, and serum aspartate transaminase (AST) and serum alanine 
transaminase (ALT) were measured using a commercially available Kit (Spinreact, Spain). 
 
Caspase 3/7 activity in melanoma 
Caspase 3/7 activity was measured using the Caspase-Glo 3/7® Assay (Promega Corp., Madison, WI, 
USA), according to the method previously described [35]. Briefly, 15 μg of total protein extracts was 
incubated with the reagent 30 min at room temperature and protected from the light. Luminescence 
was measured for 2 h, with 30 min of interval, using the GloMax®-Multi Detection System (Promega 
Corp.). 
 
Statistical analysis 
Results are expressed as mean ± standard deviation (SD) or standard error mean (SEM). Statistical 
analysis was performed using One-way ANOVA followed by Tukey Post-Hoc test and independent 
samples t-test using GraphPad Prism®5 for Windows (GraphPad Software, CA, USA). p<0.05 was 
considered statistically significant. 
 
Results  
Physicochemical characterization of Cuphen nanoliposomes 
Cuphen (Figure 1) was the selected metal complex for the current study, due to its antiproliferative 
effect against several cancer cell lines, including melanoma [30]. Long circulating nanoliposomes 
encapsulating Cuphen were prepared using the dehydration-rehydration method, followed by an 
extrusion step to reduce the mean size of the so-formed nanoformulations [30,31]. Owing to its 
hydrophilic properties, Cuphen was added after formation of the lipid film. The so-formed liposomal 
suspension was lyophilized and, afterwards, rehydration was performed in two steps with PBS buffer 
to increase Cuphen incorporation [32], following a well-established methodology that has been 
described since 1984 (Kirby and Gregoriadis, 1984). For the preparation of Cuphen nanoliposomes, 
phospholipids with different transition temperatures (Tc) were used, aiming to evaluate the influence 
of Tc on Cuphen incorporation parameters. The three main phospholipids tested were PC, DMPC and 
HPC, presenting Tc values of -6oC, +23oC and +41oC, respectively. All Cuphen nanoliposomes 
contained DSPE-PEG at a 5% molar ratio in the lipid composition, as our purpose was to develop 
formulations with long circulating properties. In fact, although some other polymers have been 
successfully tested as alternatives to PEG, this polymer still remains the golden standard for 
preparing long circulating liposomes [36-38]. Several studies have been performed to evaluate the 
influence of PEG molecular weight, the phospholipid used to be linked to the polymer and the molar 
ratio used in the lipid composition on the morphology of lipid structure formed. When liposomes were 
prepared with PEG at 8 and 12 % molar ratio, discs and mixed micelles were observed, respectively. 
Moreover, we have already assessed the in vivo profile of PEG liposomes using other compounds 
[23, 31]. 
 
In the first series of Cuphen nanoformulations (F1, F2, F3 and F4), Chol was included in the lipid 
composition. A second series of pH-sensitive nanoformulations (F5, F6 and F7) was developed to 
explore Cuphen release at the slightly acidic tumour microenvironment [28,29]. To attain this goal, 
CHEMS was included in the lipid composition since, when in contact with an acidic milieu, it becomes 
protonated, leading to bilayer disruption and subsequent drug release [29,39–41].  
In Table 1, the influence of the lipid composition on Cuphen incorporation parameters, namely final 
Cuphen to lipid ratio (loading capacity) and Incorporation Efficiency (I.E.), as well as mean size and 
zeta potential values are depicted. 
Lipid composition influences nanoliposomes permeability and, consequently, the stability of the 
incorporated drug. Bilayers constituted by phospholipids with a moderate Tc, such as DMPC (Tc = 
+23oC), are less prone to drug leakage than those containing PC (Tc = -6oC). In PC-based 
nanoliposomes, Chol is frequently included to enhance the incorporation parameters of low molecular 
weight hydrophilic compounds [42,43].  
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Cuphen nanoformulation F1 displayed an I.E. of 42% and a loading capacity of 26 nmol/µmol of lipid. 
Keeping the same molar ratio, the use of a more rigid phospholipid, DMPC, markedly reduced the 
incorporation parameters of Cuphen, with an I.E. of 9% and loading capacity of 3 nmol of Cuphen per 
µmol of lipid (F2). The reduction of Chol molar ratio in the lipid composition from 33 mol% (F2) to 16 
and 13 mol % resulted in increased incorporation parameters for F3 and F4, respectively. Moreover, 
no statistically significant differences, in terms of loading capacity, were observed between F4 
(DMPC) and F1 (PC), 19±4 and 26±8 nmol of Cuphen/µmol lipid, respectively. Overall, the use of 
DMPC as the main phospholipid instead of PC does not require the inclusion of a high molar ratio of 
Chol to stabilize Cuphen within nanoliposomes.  
For the pH-sensitive nanoliposomes, the results show that the increase on the Tc of the main 
phospholipid also led to a systematic reduction of Cuphen loading on F5, F6 and F7: 43, 34 and 28 
nmol of Cuphen/µmol lipid, respectively. All liposomal nanoformulations presented a mean size 
around 0.13 µm and a polydispersity index under 0.15, demonstrating the high homogeneity of all 
nanoformulations. Regarding surface charge, all Cuphen nanoliposomes presented a zeta potential 
close to neutrality. Based on the above results, DMPC-based nanoformulations F4 and F6 were 
selected for further studies, as both presented suitable incorporation parameters. 
 
Thermotropic behavior of Cuphen nanoliposomes: drug-lipid interactions 
The raw materials for the preparation of nanoliposomes are mainly phospholipids, and the respective 
Tc is an important parameter that will determine the packing of the phospholipid acyl chain order and, 
consequently, the fluidity of nanoliposomes. In addition, the thermodynamic behavior of lipid bilayers 
may be influenced by the incorporated drug leading to changes in the physical stability of the 
liposomal nanoformulation [44,45].  
In the present work, the influence of Cuphen on the thermodynamic behavior of nanoliposomes was 
assessed by differential scanning calorimetry (DSC). The enthalpy change (ΔH) and the Tc were 
evaluated for both loaded and unloaded nanoliposomes, and the results are depicted in Table S1. 
Calorimetric studies were performed for F4 and F6 as these were the selected formulations for in vivo 
studies. 
In terms of ΔH, no changes were observed between unloaded and loaded nanoliposomes. This effect 
may be explained by the hydrophilic properties of the copper complex and possibly reduced 
interaction with the lipid bilayer. The range of values obtained, 4.6 to 6 kJ/mol, was lower when 
comparing to pure DMPC systems, with a ΔH around 14 kJ/mol [46]. The reduction on the enthalpy 
observed might be due to the presence of Chol, CHEMS or DSPE-PEG at 13, 38 and 5 mol% in the 
lipid composition, respectively. Regarding the Tc, for the tested liposomal formulations, the values 
were quite similar ranging from 21.9 and 23ºC. Further studies to evaluate separately the influence of 
each component of the lipid composition may clarify the above observations.  
 Cuphen pH-sensitive nanoliposomes  
Tumours’ microenvironment, as in the case of melanoma, is slightly acidic, presenting pH values 
around 6, in contrast to the normal physiological pH of 7.4 [28,29], which heavily impacts cancer 
development [47,48], and it can be explored as stimuli for triggering local liposomal drug release. In 
the current work, we developed long circulating pH-sensitive nanoliposomes by including CHEMS in 
the lipid composition [29,39-41]. To validate pH-sensitive properties of F6, the quantification of the 
metallodrug still associated to nanoliposomes was assessed upon exposure to different pH 
conditions. In paralel, the stability of F4 was also evaluated as control. These studies aimed to mimic 
the pH conditions of the tumor microenvironment and to prove that, once F6 reaches tumor sites, 
Cuphen will be released. Both nanoformulations were incubated in PBS buffer at pH 4.5, 6 and 7.4, 
and the experiments were performed as described in the materials and methods section. Results are 
displayed in Figure 2. 
According to the results, a systematic reduction on Cuphen retention in nanoliposomes was 
observed for F6 when incubated in decreasing pH conditions. While at pH 7.4 the Cuphen percentage 
was approximately 90%, at pH 6 and 4.5 the respective values were 63 and 24%. Conversely, F4 did 
not display such behavior, as no statistically significant differences were observed for the three tested 
pH values, with Cuphen to lipid ratios ranging from 65-70%. These results validate our assumption: 
only F6, featuring CHEMS in the lipid composition, displays pH-sensitive properties, enabling Cuphen 
release as a function of pH. According to the literature, CHEMS pKa was found to be 5.8 when 
associated to palmitoyl phosphatidyl choline (POPC) (50:50) [49] and 5.4 in bilayers of 
DMPC:CHEMS (70:30) [50]. Moreover, the protonation of CHEMS at pH ranging from 4.5 to 6.5 has 
been described [39]. These data support the rational for using F6 as a tool for liposomal Cuphen 
release at the mildly acidic tumour microenvironment. The same effect has been reported for the 
widely described pH-sensitive lipid composition based on a fusogenic phospholipid, dioleoyl 
phosphatidyl ethanolamine (DOPE), in combination with CHEMS [39,41].  
 
Cuphen antiproliferative effects against murine melanoma cells 
Cell viability of the B16F10 murine melanoma cell line was evaluated in the absence (control) or in the 
presence of increasing concentrations of Cuphen, in both free and liposomal forms (F1, F4 and F6), 
using the MTS assay. Figure 3 illustrates the dose-response curves and the IC50 values for B16F10 
cellular viability following incubation with Free Cuphen, F1, F4 and F6. All Cuphen formulations 
presented similar IC50 values in the low micromolar range as for Free Cuphen (IC50 ca. 3-5 μM). In a 
previous work we have already evaluated the antiproliferative effect of this compound in the presence 
of a nontumorigenic human keratinocyte cell line, HaCaT [30]. The obtained results showed that both 
Cuphen and its liposomal formulations were similarly toxic towards HaCaT cells (IC50 in the range 3-5 
μM). This result is in accordance with the relevant expression for aquaporin-3 described for this 
human cell line [51]. In addition, unloaded nanoliposomes with the respective lipid composition were 
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tested, revealing no cytotoxicity towards B16F10 cells (data not shown). Although no differences 
concerning the in vitro antiproliferative effects were observed for all tested Cuphen formulations, the 
use of long circulating nanoliposomes for in vivo delivery would be advantageous for improving the 
biodistribution profile and, particularly, the accumulation at tumour sites [18,27, 36-38].  
 
Therapeutic effects of Cuphen against melanoma – influence of lipid composition and in vivo 
safety 
PC-based long circulating nanoliposomes 
Taking into account the promising cytotoxic effects against several cancer cell lines, and the absence 
of in vivo toxicity revealed by Cuphen nanoformulation F1 in previous studies [30], we proceeded with 
the evaluation of its anticancer activity in a syngeneic murine melanoma model, in comparison to Free 
Cuphen. As positive control, 5-FU, a clinically approved pro-apoptotic drug for the treatment of 
various types of cancer, including melanoma [52,53], was used. The therapeutic effect was evaluated 
in terms of tumour volume progression, expressed as relative tumour volume (RTV), and survival rate, 
as shown in Figure 4. The results show that a similar progression on tumour volume was observed for 
Cuphen nanoformulation F1 and 5-FU treatments over 15 days (Figure 4A), while Free Cuphen was 
markedly less effective. It should be mentioned that, due to the aggressiveness and exponential 
growth of melanoma mass tumours observed in this model, mice bearing tumours with an elevated 
volume had to be sacrificed before the end of the experimental protocol (Figure 4B). In this regard, 
mice treated with either Free Cuphen or 5-FU presented survival rates superior to 50%. Most 
importantly, mice receiving i.v. injections of Cuphen nanoliposomes were the only group with 100% of 
survival, as shown in Figure 4B. In addition, the ligand 1,10-phenanthroline (phen) was also 
administered in its free form as a control in the same syngeneic murine melanoma model. The results 
demonstrated that the therapeutic action of Cuphen was due to the presence of the Cu2+ complex 
(Figure S1, Supplementary data).  
DMPC-based long circulating nanoliposomes 
Aiming to eliminate the high morbidity observed in the previous model for the control group and to 
minimize animals’ suffering, a lower number of B16F10 cells (1x105) was used for melanoma tumour 
induction, that allowed to extend the experimental protocol. In the previous animal model (Figure 4), 
no relevant therapeutic benefit was achieved for mice treated with F1, when comparing to the positive 
control 5-FU. Hence, to further investigate the therapeutic activity of Cuphen nanoformulations, the 
two selected DMPC-based lipid compositions, F4 and F6, were tested in comparison to Free Cuphen. 
Thus, one week after tumour induction, mice received i.v. injections of the formulations under study, 
at a dose of 2.5 mg/kg of body weight, three times a week, for two weeks. The therapeutic effect was 
evaluated in terms of tumour volume (Figure 5A), RTV (Figure 5B), tumour weight (Figure 5C), and 
caspase 3/7 activity (Figure 5D). Animal weight was also assessed during the experimental protocol 
(Figure 5E).  
 
A major therapeutic effect was observed for F4 and F6 Cuphen nanoformulations, which significantly 
delayed tumour progression when comparing to Control and Free Cuphen mice groups. As depicted 
in Figure 5A, at the end of treatment schedule, F4 and F6 groups presented the smallest tumour 
volumes, below 1000 mm3, while 2- to 3-fold higher values were observed for Free Cuphen and 
Control groups, respectively. The therapeutic effect of Cuphen nanoliposomes was confirmed by RTV 
analysis (Figure 5B) that evaluates the tumour progression of each animal over time. While mice 
treated with F4 and F6 reached the lowest values (RTV ca. 8), Control and Free Cuphen groups 
presented RTV values around 24 and 13, respectively. In terms of both tumour volume and RTV, no 
statistically significant differences were observed between F4 and F6 at the end of the treatment, 
suggesting that, higher doses may be required to select the most effective one. In relation to tumour 
weight at the end of the treatment protocol (Figure 5C), mice receiving Cuphen nanoliposomes 
displayed the lowest values among all tested groups. Moreover, we investigated if Cuphen 
mechanism of action could involve apoptosis by determining the caspase 3/7 activity in protein 
extracts from tumour samples (Figure 5D). The results suggest that, comparing to Control group, the 
therapeutic benefit observed for mice receiving Cuphen formulations may not involve cell death by 
apoptosis, as no statistically significant differences among all tested groups were observed. Finally, 
body weight of all animals was steady over the course of the experiment and did not differ among the 
experimental groups. It is also important to highlight the fact that all groups presented a survival rate 
of 100%, comparing to the previously established model.  
 
To evaluate the safety of the Cuphen formulations at the administered dose (2.5 mg/kg), tissue index 
and hepatic biomarkers were assessed, as depicted in Table 2. In terms of tissue index, no changes 
for the analyzed organs were observed among tested groups. Tissue index provides information 
about organ development, which is constant under normal circumstances. While an increased tissue 
index indicates organ hypertrophy, congestion or edema, a decreased ratio indicates organ atrophy 
and degenerative changes [54–57].  
In addition to tissue index, and according to the FDA agency guidelines, we also evaluated hepatic 
aminotransferases – alanine aminotransferase (ALT) and aspartate aminotransferase (AST) [58]. 
Alterations in these enzymatic biomarkers allow the detection or prediction of potential harmful 
hepatic effects upon exposure to a drug or derived from metastatic conditions [59,60]. Lower values 
for AST were observed for mice receiving Cuphen nanoformulations in comparison to control group or 
mice treated with Free Cuphen. Despite all values were within the reference intervals reported by the 
mice provider, [61] these differences may demonstrate the safety advantages of the copper complex 
after incorporation in nanoliposomes. In other melanoma mice model, high values of plasmatic ALT 
have been reported indicating liver damage. However, the tumour induction was performed by 
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injecting B16 cells directly into the spleen leading to metastatic melanoma [62]. Data in Table 2 shows 
no alterations for all treated groups, demonstrating that Cuphen formulations are safe for i.v. 
administration.  
Discussion 
Although several metallodrugs display in vitro cytotoxic effects towards tumor cells, their in vivo 
therapeutic activity and progression into clinical trials is frequently hampered by low specificity to 
biological targets or de-activation of the pharmacologically active species mostly due their speciation 
in physiological conditions. To overcome these drawbacks and increase the therapeutic benefits, the 
use of a safe and efficient delivery system is of pivotal importance. It is worth mentioning that, 
recently, in the field of metallodrugs development, strategies for developing nanoformulations of the 
clinically approved anticancer platinum drugs in form of liposomes and polymers have made it to 
clinical studies. For example, a liposomal cisplatin formulation (Lipoplatin™) is already evaluated in 
several phase III studies and has been considered as a “novel cisplatin” [63, 64, 65].  
In the present work, liposomes were the selected lipid-based system aiming to preserve the 
therapeutic activity of the incorporated copper-complex while ensuring a preferential accumulation at 
tumor sites. When designing copper-complex nanoformulations, several pharmaceutical technological 
properties must be taken into consideration such as high metallodrug loadings, preservation of 
cytotoxic activity towards tumor cells and, most importantly, a significant in vivo therapeutic efficacy. 
Regarding the incorporation efficiency of Cuphen in liposomes, changing the initial Cuphen 
concentration from 500 to 750 nmol/ml resulted in an almost 2-fold increase in the loading capacity. In 
vivo, these results translated into the administration of a much lower amount of lipid for the same 
Cuphen therapeutic dose. 
In vitro, the antiproliferative effect of Cuphen formulations towards B16F10 melanoma cells is 
comparable to the one of Free-Cuphen, with IC50 in the low micromolar range. In vivo, the therapeutic 
effect of the Cuphen-formulations towards a melanoma model, evaluated in terms of tumour volume, 
RTV, tumour weight and caspase 3/7 activity, are extremely of note. The choice of the main 
phospholipid component in the lipid composition was an important factor for selecting the most 
effective Cuphen nanoformulation in vivo. In fact, DMPC-based Cuphen nanoliposomes demonstrated 
a superior antitumor activity in the murine melanoma model, an achievement that may be correlated 
with the higher Tc of DMPC in comparison to PC (as in formulation F1) and of course, Free Cuphen. 
After systemic administration, DMPC nanoliposomes are able to stabilize loaded Cuphen and, 
consequently, increase the amount of the metallodrug that reaches tumor sites. On the other hand, 
the low Tc for PC might favour a premature release of Cuphen loaded liposomes while in circulation, 
justifying the modest antitumor effect observed in the present work.  
Finally, the differences in therapeutic effect exerted by the pH sensitive formulation F6 with respect to 
the non-pH sensitive F4 were negligible, and more studies are necessary to explore the advantage of 
using different lipid compositions. Further studies to clarify the mechanism of action should also be 
performed, including AQP3 inhibition and AQP3 gene and protein expression in frozen tumor 
samples, as well as a dose response effect for this metallodrug formulation. 
Overall, the successful results obtained from this proof of concept study, devoid of hepatic 
toxic effects, renders DMPC-based Cuphen nanoliposomes an attractive candidate for melanoma 
treatment.  
 
Conclusions 
In this study, we successfully developed and explored an alternative therapeutic strategy featuring 
high potential against melanoma. Specifically, we examined the antitumour activity of the Cu(II) 
complex featuring a 1,10-phenanthroline ligand, Cuphen, in a well-established syngeneic murine 
melanoma model. Cuphen delivery to melanoma tumours was accomplished using long circulating 
nanoliposomes. In vivo data demonstrated that DMPC-based Cuphen nanoliposomes significantly 
impaired melanoma progression devoid of toxic side effects for a dose of 2.5 mg/kg of body weight. 
Higher therapeutic doses may be envisioned in further studies. Future studies should also include the 
evaluation of the kinetics of metallodrug release from the liposomes. 
To the best of our knowledge, despite the numerous reports on the anticancer effects of 
copper complexes featuring N^N donor ligands, this is the first publication that reports the potential 
therapeutic effect against melanoma of the copper complex Cuphen following its incorporation in long 
circulating nanoliposomes. Such promising anticancer effects might provide a strong basis for a 
successful bench to bedside research, ultimately benefiting melanoma patients. 
 
Future perspective 
The increasing incidence, aggressive malignancy and high mortality of metastatic melanoma 
associated to the lack of effective therapies demands the identification of new therapeutic targets. 
Certainly, copper compounds as Cuphen are likely to act via different mechanisms, including ROS 
formation and DNA damage. Furthermore, the recent report of the inhibitory effects of Cuphen 
towards the aquaporins (AQPs) may also shed light into new targets for this family of metallodrugs, 
associated to tumor cell growth, proliferation and metastasis. Taking into account that AQPs are also 
expressed in healthy tissues their modulation in pathological situations needs to be highly specific. 
The use of lipid-based systems, particularly liposomes, owning to their efficiency and ability to 
incorporate a wide array of compounds, constitutes a key strategy to control copper compounds’ 
speciation and reactivity at tumor site.  
In the present work we took advantage of the properties that pegylated liposomes present: 
long circulation times in bloodstream, extravasation into tumor interstitial space and accumulation at 
those pathological sites due to impaired lymphatic drainage, through a passive mechanism. In the 
future, the development of alternative Cuphen nanoformulations featuring specific ligands at their 
surface will allow a preferential targeting to receptors overexpressed at tumor sites. However, to 
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successfully achieve such strategy a delicate balance of selected ligands content and surface 
exposure, minimizing immunologic recognition and clearance should be accomplished. 
 In the present work proof-of-concept preclinical studies were performed in immunocompetent 
mice using murine melanoma cells. The future in vivo evaluation in a model that mimics the human 
metastatic progression of melanoma, should be envisioned. Overall the herein described therapeutic 
might provide a strong basis for translating preclinical findings to clinical trials. 
 
Summary points  in vitro and in vivo evaluation of a copper complex with high anticancer potential using a 
nanotechnological approach to enhance its therapeutic efficacy   Copper-complex nanoformulations displayed suitable incorporation parameters as well as 
thermodynamic stability preserving antiproliferative properties towards melanoma cells.   DMPC-based copper-complex nanoformulations markedly reduced tumour progression in murine 
melanoma models, in comparison to the metallodrug in the free form, and are devoid of toxic side 
effects;   These preclinical studies pave the way to the emergence of innovative and more effective 
therapies against melanoma. 
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Legends of figures 
Figure 1. Chemical structure of the Cu2+ complexes:  Casiopeína IIgly (Cas IIgly) and Cuphen. 
 
Figure 2. Stability of Cuphen-loaded nanoliposomes: influence of pH conditions. Cuphen 
nanoformulations (F4 and F6) were incubated in PBS buffer at pH 4.5, 6 or 7.4, for 90 min, at 37oC, 
under stirring. The stability was evaluated as the ratio in percentage between Cuphen to lipid ratio 
after incubation at pH 4.5, 6 or 7.4 and the Cuphen to lipid ratio before incubation, at pH 7.4. Data are 
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expressed as mean ± SD of two independent experiments with three replicates each. **p<0.01 vs pH 
6; ***p<0.001 vs pH 4.5. 
 
Figure 3. Antiproliferative effect of Cuphen towards B16F10 cells. (A) Dose-response curves for cell 
viability of B16F10 in the presence of Cuphen formulations and (B) respective IC50 values, expressed 
as mean percentage (%) of control ± SD of three independent experiments with six replicates each. 
Results correspond to cellular viability after 72 h incubation with different Cuphen concentrations (0.2 
to 12 μM), in free and liposomal forms (MTS assay). 
 
Figure 4. Therapeutic evaluation of Cuphen nanoformulation F1, Free Cuphen and 5-FU in a 
syngeneic murine melanoma model. (A) Relative tumour volume (expressed as mean ± SEM of at 
least 5 animals per group) and (B) Kaplan-Meier survival curve. Tumour induction was performed by 
a s.c. injection of 5x105 B16F10 cells. 10 days after tumour induction, mice received i.v. injections of 
the formulations under study (Cuphen and 5-FU at 2.5 and 40 mg/kg of body weight, respectively), 
three times a week, for two weeks. Control group received PBS. RTV was determined for each 
animal, as the ratio between volumes at the indicated day and volumes at the beginning of treatment.  
 
Figure 5. Therapeutic effect of Cuphen formulations in a syngeneic murine melanoma model. (A) 
Tumour volume evolution, including representative tumour images of each treated group on day 22, 
(B) Relative tumour growth (RTV), (C) Tumour weight of each mouse on day 22, (D) Caspase 3/7 
activity (Fold Change to Control), and (E) Animal weight. Tumour induction was performed by a s.c. 
injection of 1x105 B16F10 cells. One week after tumour induction, mice received i.v. injections of the 
formulations under study, at a dose of 2.5 mg/kg of body weight, three times a week, for two weeks. 
Control group received PBS. RTV was determined for each animal, as the ratio between volumes at 
the indicated day and volumes at the beginning of treatment. Results are expressed as mean ± SEM 
of at least 5 animals per group. *p<0.05 Control vs F4/F6; **p<0.01 Control vs F6; £ p<0.05 Control vs 
F6; § p<0.05 Control vs Free Cuphen/F4/F6; # p<0.05 Control vs F4/F6 and Free Cuphen vs F4. 
 
 
    
